Research Papers:

p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Fang Fang _, Jian Pan, Yi-Ping Li, Gang Li, Li-Xiao Xu, Guang-Hao Su, Zhi-Heng Li, Xing Feng and Jian Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:27422-27429. https://doi.org/10.18632/oncotarget.8320

Metrics: PDF 1879 views  |   HTML 2034 views  |   ?  


Fang Fang1, Jian Pan1, Yi-Ping Li1, Gang Li1, Li-Xiao Xu1, Guang-Hao Su1, Zhi-Heng Li1, Xing Feng1, Jian Wang1

1Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou 215025, Jiangsu, China

Correspondence to:

Jian Wang, e-mail: [email protected]

Xing Feng, e-mail: [email protected]

Keywords: PAK1, solid tumor, prognosis, survival, meta-analysis

Received: November 25, 2015     Accepted: March 14, 2016     Published: March 24, 2016


p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) expression appears to be predictive of prognosis in various solid tumors, though the evidence is not yet conclusive. We therefore performed a meta-analysis to explore the relationship between PAK1 and prognosis in patients with solid tumors. Relevant publications were searched in several widely used databases, and 15 studies (3068 patients) were included in the meta-analysis. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between PAK1 and prognosis. Associations between PAK1 expression and prognosis were observed for overall survival (HR = 2.81, 95% CI = 1.07-7.39) and disease-specific survival (HR = 2.15, 95% CI = 1.47-3.16). No such association was detected for time to tumor progression (HR = 1.78, 95% CI = 0.99-3.21).Our meta-analysis thus indicates that PAK1 expression may be a predictive marker of overall survival and disease-specific survival in patients with solid tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8320